The ranking
No public survey ranks pharma functions by total effort, so we combined cost, time, and volume data into our own ranking:
| Rank | Workload | Why it is heavy | Key figure |
|---|---|---|---|
| 1 | Clinical development | The largest cost and the longest timeline; protocols keep getting more complex | A Phase III trial costs about $55,700 a day in direct costs (Tufts CSDD) |
| 2 | Regulatory submissions and lifecycle | Every approval is followed by years of supplements, annual reports, and labeling updates | FDA’s drug center received 319,828 electronic submissions in 2025, up from 139,322 in 2014 |
| 3 | Pharmacovigilance | Adverse event volume keeps rising, and each case must be processed on deadline | FDA received about 2.2 million electronic adverse event submissions in 2025 |
| 4 | Quality and GMP compliance | Procedures, investigations, and records must be right every time | Not following written procedures was the top FDA Form 483 citation in FY2024 (184 times) |
| 5 | Commercial and medical content review | High volumes of promotional and medical material need medical, legal, and regulatory review | McKinsey puts the largest generative AI value in commercial work ($18 to 30 billion a year) |
The common thread is documents: protocols, clinical study reports, submissions, case reports, batch records, and promotional materials. Most of the effort goes into writing, checking, and cross-referencing them.
1. Clinical development: the biggest load
Cost and time.
| Measure | Figure | Source |
|---|---|---|
| Average cost per asset (top 20 pharma) | about $2.23 billion | Deloitte, 2025 |
| Phase I to filing | about 100 months, up from 93 in 2020 | Deloitte, 2025 |
| Phase I start to approval | 9.3 years in 2024 | IQVIA, 2025 |
| Direct trial cost per day | Phase III $55,716; Phase II $23,737; Phase I $7,829 | Tufts CSDD (2023 dollars) |
| Lost sales per day of delay | about $800,000 | Tufts CSDD |
| US site-based trial spending, 2023 | $30.6 billion; $24,000 to $282,000 per participant | TEConomy for PhRMA |
| Trials on assets later terminated, 2024 | about $7.7 billion | Deloitte, 2025 |
Complexity keeps rising.
- Compared with 10 years ago, protocols have 29% more endpoints and 61% more procedures (Tufts/SCRS, 2026).
- The average Phase III protocol has 301 procedures, up from 187.
- Deviations per pivotal trial have more than doubled.
- A Phase III protocol now collects nearly 6 million data points, growing about 11% a year. About a third of the procedures and data points are not core to the main endpoints (Tufts/TransCelerate).
Amendments add cost. Older Tufts data (2016) found:
- 57% of protocols had at least one substantial amendment.
- Each cost a median $535,000 in Phase III.
- About half were avoidable.
Documents are a big part of the load. Writing a clinical study report (CSR) typically takes more than 8 weeks (McKinsey). Merck reported cutting first-draft effort from 180 hours to 80 with generative AI.
2. Regulatory submissions and lifecycle
The workload does not end at approval:
- FDA’s drug center received 319,828 electronic submissions in 2025, more than twice the 2014 level (139,322). FDA’s biologics center received 97,133.
- FDA’s own paperwork estimate for 21 CFR 314 (2023):
- a new drug application (NDA) takes about 1,921 hours to prepare, across about 121 NDAs a year
- about 2,570 supplements a year take about 150 hours each
- about 3,090 annual reports take about 40 hours each
- in total, about 3.5 million hours a year
- An older industry report (2020) found that large companies each employ more than 2,000 people to keep product information current with regulators.
3. Pharmacovigilance
- FDA received 2,203,397 electronic adverse event submissions in 2025, compared with 1,026,314 in 2014.
- In Deloitte’s 2019 survey, case processing took 40 to 85% of pharmacovigilance budgets, and case volumes grew 10 to 15% a year.
- Productivity ranged from 300 to 400 case reports per full-time employee, up to 1,000 to 2,000 at scale.
4. Quality and GMP
In FY2024, FDA issued 561 Form 483s to drug manufacturers. The most cited problems were about procedures and investigations:
| FY2024 citation | Count |
|---|---|
| Written procedures not followed (21 CFR 211.22(d)) | 184 |
| Discrepancies not investigated (211.192) | 116 |
| Procedures missing (211.100(a)) | 109 |
| Lab controls not scientifically sound (211.160(b)) | 109 |
FDA’s FY2024 pharmaceutical quality report counted 105 quality warning letters, the most in five years, and 421 recalled products. Seventeen percent of drug Form 483s cited the stability program. The burden is ongoing documentation and investigation, not one-off fixes.
5. Where AI and automation help
McKinsey (2024) estimates generative AI’s annual value in pharma at $60 to 110 billion:
| Area | Estimated annual value |
|---|---|
| Commercial | $18 to 30 billion |
| Research | $15 to 28 billion |
| Clinical development | $13 to 25 billion |
| Operations | $4 to 7 billion |
| Medical affairs | $3 to 5 billion |
The parts add up to less than the headline range, and McKinsey does not explain the gap.
Task-level examples:
- Medical writing: costs could fall 20 to 30% now, and 50 to 70% as tools mature.
- Regulatory submissions: could be about 40% faster.
- Merck’s clinical study reports: time to completion fell from 2 to 3 weeks to 3 to 4 days, and errors fell by half.
The heaviest workloads are the best targets because they are document-heavy and rule-based. AI drafts, checks, and cross-references; people stay accountable for decisions.
Using this in AI and RAG
- Index the rules behind each workload: ICH guidelines, 21 CFR 312 and 314, pharmacovigilance and GMP regulations.
- Index your own documents by workload: protocols, clinical study reports, submissions, case reports, deviations.
- Measure before and after: hours per document, error rates, cycle times.
- Keep humans signing off on clinical, safety, and quality decisions.
Common mistakes
- Automating low-volume tasks while the heavy document work stays manual.
- Ignoring protocol design, where a third of the data collected is not core.
- Treating AI drafts as final without review.
- Measuring adoption instead of time saved.
Checklist
- Workloads ranked by hours and cost in your own company
- Rules and internal documents indexed per workload
- Baseline metrics captured
- Human sign-off defined
How AskDona helps
AskDona targets the document-heavy part of these workloads. It checks protocols, clinical study reports, submission sections, safety narratives, and deviation reports against the rules and your own source documents, and cites the passage behind each finding.
Run a sample document evidence check
AskDona shows the evidence; your clinical, regulatory, safety, and quality teams decide.
Editor’s note. This article is general information. The ranking is our editorial judgment based on the cited data, because no public source ranks pharma functions by total effort. Some figures (amendment costs from 2016, pharmacovigilance budgets from 2019) are older and marked as such.
FAQ
What is the most expensive workload in pharma? Clinical development. A Phase III trial costs about $55,700 a day in direct costs, and an asset averages about $2.23 billion to develop.
How many submissions does FDA receive for drugs? CDER received 319,828 electronic submissions in 2025.
How many adverse event reports does FDA receive? About 2.2 million electronic submissions in 2025.
What is the most common FDA GMP finding? Not following written procedures, cited 184 times in FY2024.
References
All pages opened and checked by October 30, 2026.